Home  >  News
Corporate + Font Resize -

VAV Life Sciences launches India’s first Phospholipid manufacturing plant at Mirjole, Ratnagiri

Our Bureau, Mumbai
Tuesday, January 31, 2017, 17:45 Hrs  [IST]

One of the top phospholipid manufacturers, VAV Life Sciences inaugurated its cGMP compliant Phospholipid manufacturing plant at Mirjole, Ratnagiri, Maharashtra. The plant is set up in India considering the emerging healthcare applications of lecithins and phospholipids in functional foods, nutritional supplements, novel pharmaceuticals and cosmetics.

With the plant, the company will mark products manufactured at the factory with a ‘Made in India’ label and will export 80 per cent of them to North America, Europe, Asia and ROW region. The existing brands manufactured include leciva, lipova, oleova.

The first phase of the plant is spread across 30,000 sq ft with EU cGMP standard facilities. The facility utilises state-of-the-art technology, which allows the production of its all-natural higher grade of phospholipids ingredient in accordance with the global industry standards. Most phospholipids are derived from nature, hence classified as Generally Recognised as Safe (GRAS) by US FDA. Through the plant, VAV Life Sciences will be building distinct production lines for refined soya, egg and synthetic Phospholipids. Ratnagiri location was the first choice to set up this plant due to its excellent infrastructure facilities, conducive business environment, suitable weather conditions and quality trained manpower.

Highlighting the importance of Phospholipids in global markets, Arun Kedia, CMD of VAV Life Sciences Pvt Ltd. says, “Phospholipids help drugs to target specific organs, tissues or even cells in the human body thus increases efficacy and eliminates toxicity. The increasing demand for green and naturally sourced ingredients, coupled with increasing consumer awareness towards healthy lifestyle, has raised demand for phospholipids. Besides, the nascent market for phospholipids is projected to reach USD 1.1 Billion by 2020 globally.” In addition, he shares that “High acceptance, awareness, and demand for phospholipids-based products in the nutrition and health supplements industry has further triggered demand in North American and European region as well.”

The plant was inaugurated in Ratnagiri by Ravindra Waikar, Maharashtra's minister of state for Housing, Higher and Technical Education and guardian minister of Ratnagiri. At the occasion, Waikar said "This project is a role model for Phospholipid industry. It shall contribute to the nation by being its 1st World class, c-GMP Standards compliant, manufacturing plant for liposomal nanotechnology ingredients.”

VAV Life Sciences Pvt Ltd is committed to produce pure, high-quality products with minimal damage to the environment, built as ‘zero discharge’. In addition, the advanced and well-equipped R&D facility is designed to support product development and research. It also offers ingredient systems that are supported by the highest level of scientific data, technical quality and safety.

Started in 2003, VAV Life Sciences Pvt Ltd is an innovation driven company with a niche focus to provide lecithins and phospholipids to the pharmaceutical, functional nutrition and cosmeceutical sectors. With plethora of products the company caters to segments like food, sports nutrition, cosmetics & pharma.

VAV is committed to unique R&D to effectively and efficiently tap the therapeutic properties of natural products and improve the health and quality of people's lives worldwide. It is the fifth company globally to master this rare technology and the second to commercially produce pharmaceutical grade phospholipids. Being an internationally oriented organization, the company’s reach is spread all around the world, 57 per cent being Europe & 23 per cent North America. VAV has received ‘India’s best SME Award 2013’ under the innovation category by Business Today and ‘D&B SME Excellence Award 2015’ under the category of Chemicals and Pharmaceuticals sector.


* Name :     
* Email :    
  Website :  
Anuj Goel Feb 1, 2017 1:54 PM
Proud moment for the Indian pharmaceutical industry. May potentially revolutionize NDDS & liposomal formulations.
Copyright © 2016 Saffron Media Pvt. Ltd |